Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04340596 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
A Phase 1 study of HIV Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
- 14
- Study locations
NCT04340596 is a Phase 1 study of HIV Infection that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 118 participants, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (51% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT04340596, a Phase 1 study of HIV Infection, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Conditions Studied
Interventions
- BIOLOGICAL VRC07-523LS
- BIOLOGICAL N-803 (IL-15 Superagonist)
- BIOLOGICAL 10-1074
Study Locations (14)
California
- UCLA CARE Center CRS - Los Angeles
- UCSD Antiviral Research Center CRS (Site ID: 701) - San Diego
- University of California, San Fransisco HIV/AIDS CRS - San Francisco
New York
- Columbia P&S CRS - New York
- Weill Cornell Uptown CRS (Site ID: 7803) - New York
Alabama
- Alabama CRS (Site ID# 31788) - Birmingham
District of Columbia
- Whitman-Walker Institute, Inc. CRS (Site ID: 31791) - Washington D.C.
Illinois
- Northwestern University CRS - Chicago
Massachusetts
- Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101) - Boston
Missouri
- Washington University Therapeutics (WT) CRS - St Louis
New Jersey
- New Jersey Medical School Clinical Research Center CRS [Site ID: 31786] - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04340596
The ClinicalTrials.gov registry entry for NCT04340596 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 73 other HIV Infection trials with a reported enrollment target (51% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 3 interventions - of which VRC07-523LS is the first listed.
NCT04340596 reports 14 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT04340596 about?
NCT04340596 is a clinical study titled "Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption". The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
What is the current status of trial NCT04340596?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2021-05-21. Estimated completion is 2026-12-30.
What conditions does trial NCT04340596 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT04340596?
The interventions under investigation include: VRC07-523LS (BIOLOGICAL), N-803 (IL-15 Superagonist) (BIOLOGICAL), 10-1074 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04340596?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04340596 being conducted?
This trial has 14 study locations across Alabama, California, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
RECRUITING · Phase 1
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Twins Study of Gene Therapy for HIV Infection
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.